

Dialogues in Contraception[®], Volume 11, Issue 3

References

Please click on the Reference Section below to go directly to that section's reference list. You can also scroll from this page to view all of the references.

Reference Sections

[Advances in Sterilization](#)

[Assessing Costs and Improving Access to Contraception](#)

[Extended Combination Hormonal Contraceptive Regimens and Menstrual Suppression](#)

Advances in Sterilization

1. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. *Adv Data*. 2004;350:1-35.
2. Westhoff C, Davis A. Tubal sterilization: focus on the U.S. experience. *Fertil Steril*. 2000;73:913-922.
3. MacKay AP, Kieke BA Jr, Koonin LM, Beattie K. Tubal sterilization in the United States, 1994-1996. *Fam Plann Perspect*. 2001;33:161-165.
4. Pati S, Cullins V. Female sterilization. Evidence. *Obstet Gynecol Clin North Am*. 2000;27:859-899.
5. Planned Parenthood Federation of America. Tubal sterilization. Available at: <http://www.plannedparenthood.org/birth-control-pregnancy/birth-control/tubal-sterilization.htm>. Accessed June 13, 2007.
6. Speroff L, Darney PD. Sterilization. In: *A Clinical Guide for Contraception*. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005: Chapter 12.
7. Pollack AE, Carignan CS, Jacobstein R. Female and male sterilization. In: *Contraceptive Technology*. 18th ed. New York, NY: Ardent Media Inc.; 2004.
8. Kulier R, Boulvain M, Walker D, De Candolle G, Campana A. Minilaparotomy and endoscopic techniques for tubal sterilisation. *Cochrane Database Syst Rev*. 2004;CD001328.
9. Jamieson DJ, Hillis SD, Duerr A, Marchbanks PA, Costello C, Peterson HB. Complications of interval laparoscopic tubal sterilization: findings from the United States Collaborative Review of Sterilization. *Obstet Gynecol*. 2000;96:997-1002.
10. Hastings-Tolsma M, Nodine P, Teal SB. Essure: hysteroscopic sterilization. *J Midwifery Womens Health*. 2006;51:510-514.
11. Abbott J. Transcervical sterilization. *Best Pract Res Clin Obstet Gynaecol*. 2005;19:743-756.
12. Essure: Instructions for Use. San Carlos, Calif: Conceptus Incorporated; 2002.

13. Kerin JF, Cooper JM, Price T, et al. Hysteroscopic sterilization using a micro-insert device: results of a multicentre Phase II study. *Hum Reprod.* 2003;18:1223-1230.
14. Cooper JM, Carignan CS, Cher D, Kerin JF. Microinsert nonincisional hysteroscopic sterilization. *Obstet Gynecol.* 2003;102:59-67.
15. Essure FAQ: the Essure clinical trial information. Available at: <http://www.essuremd.com/Home/bTheEssureProcedureb/bFAQsb/tabid/59/Default.aspx>. Accessed June 5, 2007.
16. Wilson EW. Sterilization. *Baillieres Clin Obstet Gynaecol.* 1996;10:103-119.
17. Cook LA, Pun A, van Vliet H, Gallo MF, Lopez LM. Scalpel versus no-scalpel incision for vasectomy. *Cochrane Database Syst Rev.* 2007;CD004112.
18. Dassow P, Bennett JM. Vasectomy: an update. *Am Fam Physician.* 2006;74:2069-2074.
19. Sokal D, Irsula B, Chen-Mok M, Labrecque M, Barone MA. A comparison of vas occlusion techniques: cautery more effective than ligation and excision with fascial interposition. *BMC Urol.* 2004;4:12.
20. Sokal D, Irsula B, Hays M, Chen-Mok M, Barone MA. Vasectomy by ligation and excision, with or without fascial interposition: a randomized controlled trial [ISRCTN77781689]. *BMC Med.* 2004;2:6.
21. Griffin T, Tooher R, Nowakowski K, Lloyd M, Maddern G. How little is enough? The evidence for post-vasectomy testing. *J Urol.* 2005;174:29-36.
22. Barone MA, Nazerali H, Cortes M, Chen-Mok M, Pollack AE, Sokal D. A prospective study of time and number of ejaculations to azoospermia after vasectomy by ligation and excision. *J Urol.* 2003;170:892-896.
23. Awsare NS, Krishnan J, Boustead GB, Hanbury DC, McNicholas TA. Complications of vasectomy. *Ann R Coll Surg Engl.* 2005;87:406-410.
24. Labrecque M, Hays M, Chen-Mok M, Barone MA, Sokal D. Frequency and patterns of early recanalization after vasectomy. *BMC Urol.* 2006;6:25.
25. Schwingl PJ, Guess HA. Safety and effectiveness of vasectomy. *Fertil Steril.* 2000;73:923-936.

26. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. *Am J Obstet Gynecol.* 1996;174:1161-1170.
27. Jamieson DJ, Costello C, Trussell J, Hillis SD, Marchbanks PA, Peterson HB. The risk of pregnancy after vasectomy. *Obstet Gynecol.* 2004;103:848-850.
28. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. *Contraception.* 2007;75(suppl):S70-S75.
29. Hatcher R, Trussell J, Stewart FH. Contraceptive efficacy. In: *Contraceptive Technology.* 18th ed. New York, NY: Ardent Media Inc; 2004.
30. Pollack A. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 46, September 2003. (Replaces technical bulletin number 222, April 1996). *Obstet Gynecol.* 2003;102:647-658.
31. Bahamondes L, Faundes A, Sobreira-Lima B, Lui-Filho JF, Pecci P, Matera S. TCU 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. *Contraception.* 2005;72:337-341.
32. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNG 20) and the Copper T380 Ag IUDs. *Contraception.* 1991;44:473-480.
33. Ronnerdag M, Odland V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system: a follow-up study over 12 years of continuous use. *Acta Obstet Gynecol Scand.* 1999;78:716-721.
34. Inki P. Long-term use of the levonorgestrel-releasing intrauterine system. *Contraception.* 2007;75(suppl):S161-S166.
35. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of ectopic pregnancy after tubal sterilization. *N Engl J Med.* 1997;336:762-767.
36. Hendrix NW, Chauhan SP, Morrison JC. Sterilization and its consequences. *Obstet Gynecol Surv.* 1999;54:766-777.
37. Hillis SD, Marchbanks PA, Tylor LR, Peterson HB. Higher hysterectomy risk for sterilized than nonsterilized women: findings from the U.S. Collaborative Review of Sterilization. *Obstet Gynecol.* 1998;91:241-246.

38. Shy KK, Stergachis A, Grothaus LG, Wagner EH, Hecht J, Anderson G. Tubal sterilization and risk of subsequent hospital admission for menstrual disorders. *Am J Obstet Gynecol*. 1992;166:1698-1705.
39. New York State Department of Health. New York State Medicaid Program provider manual: inpatient. Available at: https://www.emedny.org/ProviderManuals/Inpatient/PDFS/Inpatient_Policy_Guidelines2006-1.pdf. Accessed September 14, 2007.
40. Mattinson A, Mansour D. Female sterilisation: is it what women really want or are alternative contraceptive methods acceptable? *J Fam Plann Reprod Health Care*. 2006;32:181-183.
41. Baill IC, Cullins VE, Pati S. Counseling issues in tubal sterilization. *Am Fam Physician*. 2003;67:1287-1294.
42. Hillis SD, Marchbanks PA, Tylor LR, Peterson HB. Poststerilization regret: findings from the United States Collaborative Review of Sterilization. *Obstet Gynecol*. 1999;93:889-895.
43. Jamieson DJ, Kaufman SC, Costello C, Hillis SD, Marchbanks PA, Peterson HB. A comparison of women's regret after vasectomy versus tubal sterilization. *Obstet Gynecol*. 2002;99:1073-1079.
44. Kelekci S, Erdemoglu E, Kutluk S, Yilmaz B, Savan K. Risk factors for tubal ligation: regret and psychological effects Impact of Beck Depression Inventory. *Contraception*. 2005;71:417-420.
45. Wilcox LS, Zeger SL, Chu SY, Peterson HB, Eaker ED. Risk factors for regret after tubal sterilization: 5 years of follow-up in a prospective study. *Fertil Steril*. 1991;55:927-933.
46. Curtis KM, Mohllajee AP, Peterson HB. Regret following female sterilization at a young age: a systematic review. *Contraception*. 2006;73:205-210.
47. Trussell J, Guilbert E, Hedley A. Sterilization failure, sterilization reversal, and pregnancy after sterilization reversal in Quebec. *Obstet Gynecol*. 2003;101:677-684.
48. Moseman CP, Robinson RD, Bates GW Jr, Propst AM. Identifying women who will request sterilization reversal in a military population. *Contraception*. 2006;73:512-515.
49. Schmidt JE, Hillis SD, Marchbanks PA, Jeng G, Peterson HB. Requesting information about and obtaining reversal after tubal sterilization: findings

from the U.S. Collaborative Review of Sterilization. *Fertil Steril*. 2000;74:892-898.

50. Costello C, Hillis SD, Marchbanks PA, Jamieson DJ, Peterson HB. The effect of interval tubal sterilization on sexual interest and pleasure. *Obstet Gynecol*. 2002;100:511-517.
51. Peterson HB, Jeng G, Folger SG, Hillis SA, Marchbanks PA, Wilcox LS, for the U.S. Collaborative Review of Sterilization Working Group. The risk of menstrual abnormalities after tubal sterilization. *N Engl J Med*. 2000;343:1681-1687.
52. Gentile GP, Helbig DW, Zacur H, Park T, Lee YJ, Westhoff CL. Hormone levels before and after tubal sterilization. *Contraception*. 2006;73:507-511.
53. Kelekci S, Yilmaz B, Yakut Y, Yasar L, Savan K, Sonmez S. Hormonal and ovarian stromal blood supply changes after laparoscopic tubal sterilization: a prospective controlled study. *Contraception*. 2006;73:279-283.
54. Dede FS, Dilbaz B, Akyuz O, Caliskan E, Kurtaran V, Dilbaz S. Changes in menstrual pattern and ovarian function following bipolar electrocauterization of the fallopian tubes for voluntary surgical contraception. *Contraception*. 2006;73:88-91.
55. Nelson DB, Sammel MD, Freeman EW, Gracia CR, Liu L, Langan E. Tubal ligation does not affect hormonal changes during the early menopausal transition. *Contraception*. 2005;71:104-110.
56. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer: a prospective study. *JAMA*. 1993;270:2813-2818.
57. Miracle-McMahill HL, Calle EE, Kosinski AS, et al. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. *Am J Epidemiol*. 1997;145:349-357.
58. Rosenblatt KA, Thomas DB, and The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. *Cancer Epidemiol Biomarkers Prev*. 1996;5:933-935.
59. Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. *Am J Epidemiol*. 1991;134:362-369.

60. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. *Am J Epidemiol.* 1992;136:1212-1220.
61. Bertero E, Hallak J, Gromatzky C, Lucon AM, Arap S. Assessment of sexual function in patients undergoing vasectomy using the international index of erectile function. *Int Braz J Urol.* 2005;31:452-458.
62. Moller H, Knudsen LB, Lynge E. Risk of testicular cancer after vasectomy: cohort study of over 73 000 men. *Br Med J.* 1994;309:295-299.
63. Cox B, Sneyd MJ, Paul C, Delahunt B, Skegg DC. Vasectomy and risk of prostate cancer. *JAMA.* 2002;287:3110-3115.
64. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Cancer and cardiovascular disease after vasectomy: an epidemiological database study. *Fertil Steril.* 2005;84:1438-1443.
65. Nienhuis H, Goldacre M, Seagroatt V, Gill L, Vessey M. Incidence of disease after vasectomy: a record linkage retrospective cohort study. *BMJ.* 1992;304:743-746.
66. Chacko JA, Zafar MB, McCallum SW, Terris MK. Vasectomy and prostate cancer characteristics of patients referred for prostate biopsy. *J Urol.* 2002;168:1408-1411.
67. Zhu K, Stanford JL, Daling JR, et al. Vasectomy and prostate cancer: a case-control study in a health maintenance organization. *Am J Epidemiol.* 1996;144:717-722.
68. Peterson HB, Howards SS. Vasectomy and prostate cancer: the evidence to date. *Fertil Steril.* 1998;70:201-203.
69. Coady SA, Sharrett AR, Zheng ZJ, Evans GW, Heiss G. Vasectomy, inflammation, atherosclerosis and long-term followup for cardiovascular diseases: no associations in the atherosclerosis risk in communities study. *J Urol.* 2002;167:204-207.
70. Yossry M, Aboulghar M, D'Angelo A, Gillett W. In vitro fertilisation versus tubal reanastomosis (sterilisation reversal) for subfertility after tubal sterilisation. *Cochrane Database Syst Rev.* 2006;3:CD004144.
71. Sitko D, Commenges-Ducos M, Roland P, Papaxanthos-Roche A, Horovitz J, Dallay D. IVF following impossible or failed surgical reversal of tubal sterilization. *Hum Reprod.* 2001;16:683-685.

72. Feinberg EC, Levens ED, DeCherney AH. Infertility surgery is dead: only the obituary remains? *Fertil Steril*. May 15, 2007; [E pub ahead of print].
73. The Practice Committee of the American Society for Reproductive Medicine. Vasectomy reversal. *Fertil Steril*. 2006;86(suppl):S268-S271.
74. Fuchs EF, Burt RA. Vasectomy reversal performed 15 years or more after vasectomy: correlation of pregnancy outcome with partner age and with pregnancy results of in vitro fertilization with intracytoplasmic sperm injection. *Fertil Steril*. 2002;77:516-519.
75. Huang HC, Hsieh ML, Huang ST, Tsui KH, Lai RH, Chang PL. Microsurgical vasectomy reversal: ten-years' experience in a single institute. *Chang Gung Med J*. 2002;25:453-457.
76. Planned Parenthood Federation of America. Vasectomy. Available at: <http://www.plannedparenthood.org/birth-control-pregnancy/birth-control/vasectomy.htm>. Accessed June 13, 2007.
77. Silber SJ, Grotjan HE. Microscopic vasectomy reversal 30 years later: a summary of 4010 cases by the same surgeon. *J Androl*. 2004;25:845-859.

Assessing Costs and Improving Access to Contraception

1. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. *Perspect Sex Reprod Health*. 2006;38:90-96.
2. Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? *Am J Obstet Gynecol*. 2007;196:412e1-412e7.
3. Stewart FH, Harper CC, Ellertson CE, Grimes DA, Sawaya GF, Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence. *JAMA*. 2001;285:2232-2239.
4. Scott A, Glasier AF. Are routine breast and pelvic examinations necessary for women starting combined oral contraception? *Hum Reprod Update*. 2004;10:449-452.
5. Phillips KA, Stotland NE, Liang S-Y, Spetz J, Haas JS, Oren E. Out-of-pocket expenditures for oral contraceptives and number of packs per purchase. *J Am Med Womens Assoc*. 2004;59:36-42.
6. Meckstroth KR. Physical examination before initiating hormonal contraception: what is necessary? *Am Fam Physician*. 2006;74:32, 34.
7. Frost JJ, Singh S, Finer LB. U.S. women's one-year contraceptive use patterns, 2004. *Perspect Sex Reprod Health*. 2007;39:48-55.
8. Espey E, Cosgrove E, Ogburn T. Family planning American style: why it's so hard to control birth in the US. *Obstet Gynecol Clin North Am*. 2007;34:1-17.
9. Reproductive Health Technologies Project. The unfinished revolution in contraception: convenience, consumer access and choice. 2004. Available at: <http://www.rhtp.org/contraception>. Accessed June 11, 2007.
10. Planned Parenthood Federation of America. Diaphragms, caps, and shields. Available at: <http://www.plannedparenthood.org/birth-control-pregnancy/birth-control/diaphragms-caps-and-shields.htm>. Accessed July 24, 2007.
11. Red Book [book on CD-ROM]. Vol 44. Thomson Micromedex; 2007.
12. Planned Parenthood Federation of America. Female condom. Available at: <http://www.plannedparenthood.org/birth-control-pregnancy/birth-control/female-condom.htm>. Accessed July 9, 2007.

13. Mayo Foundation for Medical Education and Research. Cervical cap: weigh pros, cons of this contraceptive method. Available at: <http://www.mayoclinic.com/print/cervical-cap/BI00007>. Accessed July 9, 2007.
14. Planned Parenthood Federation of America. Tubal sterilization. Available at: <http://www.plannedparenthood.org/birth-control-pregnancy/birth-control/tubal-sterilization.htm>. Accessed June 13, 2007.
15. Mayo Clinic finds new female sterilization technique not only quicker and easier for patients, but cheaper. Available at: <http://www.mayoclinic.org/news2004-rst/2512.html>. Accessed July 6, 2007.
16. Planned Parenthood Federation of America. Vasectomy. Available at: <http://www.plannedparenthood.org/birth-control-pregnancy/birth-control/vasectomy.htm>. Accessed June 13, 2007.
17. Kaiser Family Foundation. Women's health data book: highlights. A profile of women's health in the United States. Available at: <http://www.kff.org/womenshealth/6004-index.cfm>. Accessed June 8, 2007.
18. Demchak C. Bridging the gap: the role of individual health insurance coverage. *AcademyHealth Findings Brief*. 2006;9:1-4.
19. Frost JJ. Public or private providers? U.S. women's use of reproductive health services. *Fam Plann Perspect*. 2001;33:4-12.
20. Hock-Long L, Herceg-Baron R, Cassidy AM, Whittaker PG. Access to adolescent reproductive health services: financial and structural barriers to care. *Perspect Sex Reprod Health*. 2003;35:144-147.
21. Chaker AM. College students face rising birth-control prices. *Wall Street Journal*. July 26, 2007; D1.
22. Sonfield A, Gold RB. U.S. insurance coverage of contraceptives and the impact of contraceptive coverage mandates, 2002. *Perspect Sex Reprod Health*. 2004;36:72-79.
23. Shrank WH, Ettner SL, Glassman P, Asch SM. A bitter pill: formulary variability and the challenge to prescribing physicians. *J Am Board Fam Pract*. 2004;17:401-407.
24. Kaiser Family Foundation. Prescription drug trends fact sheet – May 2007 update. Available at: <http://www.kff.org/rxdrugs/3057.cfm>. Accessed June 8, 2007.

25. Foster DG, Parvataneni R, de Bocanegra HT, Lewis C, Bradsberry M, Darney P. Number of oral contraceptive pill packages dispensed, method continuation, and costs. *Obstet Gynecol*. 2006;108:1107-1114.
26. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. *Arch Intern Med*. 2006;166:332-337.
27. Dailard C. The cost of contraceptive insurance coverage. *Guttmacher Rep Public Policy*. March 2003;12-13.
28. Golub D, Gartner EC. Equity in prescription insurance and contraceptive coverage. Available at: <http://www.plannedparenthood.org/news-articles-press/politics-policy-issues/birth-control-access-prevention/prescription-insurance-6548.htm>. Accessed May 31, 2007.
29. Lindberg LD, Frost JJ, Sten C, Dailard C. The provision and funding of contraceptive services at publicly funded family planning agencies: 1995-2003. *Perspect Sex Reprod Health*. 2006;38:37-45.
30. Lindberg LD, Frost JJ, Sten C, Dailard C. Provision of contraceptive and related services by publicly funded family planning clinics, 2003. *Perspect Sex Reprod Health*. 2006;38:139-147.
31. H.R. 2412: To require equitable coverage of prescription contraceptive drugs and devices and contraceptive services under health plans. Available at: <http://www.govtrack.us/congress/billtext.xpd?bill=h110-2412>. Accessed June 8, 2007.
32. The Guttmacher Institute. Insurance coverage of contraceptives. Available at: <http://www.guttmacher.org/statecenter/spibs>. Accessed May 31, 2007.
33. Lenaz M. Women's health insurance coverage of contraception. *Manag Care Interface*. 2005;18(suppl A):23-24.
34. Kaunitz AM, Shields WC. Contraceptive equity and access in the United States: a 2005 update. *Contraception*. 2005;71:317-318.
35. Sonnenberg FA, Burkman RT, Hagerty CG, Speroff L, Speroff T. Costs and net health effects of contraceptive methods. *Contraception*. 2004;69:447-459.
36. Trussell J, Leveque JA, Koenig JD, et al. The economic value of contraception: a comparison of 15 methods. *Am J Public Health*. 1995;85:494-503.

37. Trussell J. The cost of unintended pregnancy in the United States. *Contraception*. 2007;75:168-170.
38. Trussell J, Koenig J, Stewart F, Darroch JE. Medical care cost savings from adolescent contraceptive use. *Fam Plann Perspect*. 1997;29:248-255, 295.
39. Phillips CJ. Economic analysis of long-term reversible contraceptives. Focus on Implanon[®]. *Pharmacoeconomics*. 2000;17:209-221.
40. Chiou C-F, Trussell J, Reyes E, et al. Economic analysis of contraceptives for women. *Contraception*. 2003;68:3-10.
41. Sawaya GF, Harper C, Balistreri E, Boggess J, Darney P. Cervical neoplasia risk in women provided hormonal contraception without a Pap smear. *Contraception*. 2001;63:57-60.
42. Dixon HS. Pelvic exam prerequisite to hormonal contraceptives: unjustified infringement on constitutional rights, governmental coercion, and bad public policy. *Harv Women's Law J*. 2004;27:177-233.
43. Harper C, Balistreri E, Boggess J, Leon K, Darney P. Provision of hormonal contraceptives without a mandatory pelvic examination: the First Stop demonstration project. *Fam Plann Perspect*. 2001;33:13-18.
44. Lesnewski R, Prine L. Initiating hormonal contraception. *Am Fam Physician*. 2006;74:105-112.
45. Speroff L, Darney PD. Oral contraception. In: *A Clinical Guide for Contraception*. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:Chapter 2.
46. Hatcher RA, Nelson AL. Combined hormonal contraceptive methods. In: *Contraceptive Technology*. 18th ed. New York, NY: Ardent Media Inc.; 2004.
47. Moreau C, Trussell J, Gilbert F, Bajos N, Bouyer J. Oral contraceptive tolerance: does the type of pill matter? *Obstet Gynecol*. 2007;109:1277-1285.
48. Mirena health care plan coverage. Available at: <http://www.mirena-us.com/coverage.html>. Accessed August 9, 2007.
49. Paying for ParaGard. Available at: <http://www.paragard.com/paragard/custom.php?refer=ParaGard:%20QA>. Accessed August 9, 2007.

Extended Combination Hormonal Contraceptive Regimens and Menstrual Suppression

1. Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception—an international study on acceptability. *Contraception*. 2003;67:1-8.
2. Loudon NB, Foxwell M, Potts DM, Guild AL, Short RV. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. *Br Med J*. 1977;2:487-490.
3. Edelman A. Menstrual nirvana: amenorrhea through the use of continuous oral contraceptives. *Curr Womens Health Rep*. 2002;2:434-438.
4. Christopher LA, Miller L. Women in war: operational issues of menstruation and unintended pregnancy. *Mil Med*. 2007;172:9-16.
5. Hitchcock CL, Prior JC. Evidence about extending the duration of oral contraceptive use to suppress menstruation. *Womens Health Issues*. 2004;14:201-211.
6. Andrist LC, Hoyt A, Weinstein D, McGibbon C. The need to bleed: women's attitudes and beliefs about menstrual suppression. *J Am Acad Nurse Pract*. 2004;16:31-37.
7. Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. *Contraception*. 2004;70:359-363.
8. Association of Reproductive Health Professionals. Choosing when to menstruate: the role of extended contraception. Available at: <http://www.arhp.org/healthcareproviders/cme/onlinecme/extendedregimencp/index.cfm?ID=328>. Accessed July 6, 2007.
9. Sulak PJ, Buckley T, Kuehl TJ. Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives. *Contraception*. 2006;73:41-45.
10. Edelman A, Lew R, Cwiak C, Nichols M, Jensen J. Acceptability of contraceptive-induced amenorrhea in a racially diverse group of US women. *Contraception*. 2007;75:450-453.
11. Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. *Contraception*. 2006;74:359-366.

12. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. *Drugs*. 2004;64:2447-2462.
13. Gerschultz KL, Sucato GS, Hennon TR, Murray PJ, Gold MA. Extended cycling of combined hormonal contraceptives in adolescents: physician views and prescribing practices. *J Adolesc Health*. 2007;40:151-157.
14. Sucato GS, Gerschultz KL. Extended cycle hormonal contraception in adolescents. *Curr Opin Obstet Gynecol*. 2005;17:461-465.
15. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. *Contraception*. 2003;67:9-13.
16. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. *Obstet Gynecol*. 2001;98:771-778.
17. Anderson FD, Hait H, the Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. *Contraception*. 2003;68:89-96.
18. Miller L, Verhoeven CHJ, Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. *Obstet Gynecol*. 2005;106:473-482.
19. Stewart FH, Kaunitz AM, LaGuardia KD, Karvois DL, Fisher AC, Friedman AJ, for the ORTHO EVRA Extended Regimen Study Group. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. *Obstet Gynecol*. 2005;105:1389-1396.
20. LaGuardia KD, Stewart F, Kaunitz AM, Westhoff CL. Comparison of bleeding/spotting profiles between an extended regimen and a cyclic regimen of transdermal norelgestromin/ethinyl estradiol during the first 56 days of treatment. *Contraception*. 2005;72:230.
21. Foidart JM, Sulak PJ, Schellschmidt I, Zimmermann D, The Yasmin[®] Extended Regimen Study Group. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. *Contraception*. 2006;73:34-40.
22. Anderson FD, Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. *Am J Obstet Gynecol*. 2006;195:92-96.

23. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. *Contraception*. 2006;74:439-445.
24. Steinauer J, Autry AM. Extended cycle combined hormonal contraception. *Obstet Gynecol Clin North Am*. 2007;34:43-55.
25. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. *Fertil Steril*. 2003;80:560-563.
26. Mishell DR Jr. Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations. *Contraception*. 2005;71:304-305.
27. Sulak PJ. Ovulation suppression of premenstrual symptoms using oral contraceptives. *Am J Manag Care*. 2005;11:S492-S497.
28. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. *Am J Obstet Gynecol*. 2006;195:1311-1319.
29. Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. *Headache*. 2007;47:27-37.
30. LaGuardia KD, Fisher AC, Bainbridge JD, LoCoco JM, Friedman AJ. Suppression of estrogen-withdrawal headache with extended transdermal contraception. *Fertil Steril*. 2005;83:1875-1877.
31. Edelman A, Gallo MF, Nichols MD, Jensen JT, Schulz KF, Grimes DA. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. *Hum Reprod*. 2006;21:573-578.
32. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle versus cyclic use of combined oral contraceptives for contraception. *Cochrane Database Syst Rev*. 2005;CD004695.
33. Aubeny E, Buhler M, Colau JC, Vicaut E, Zadikian M, Childs M. The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives. *Eur J Contracept Reprod Health Care*. 2004;9:267-277.

34. Heikinheimo O. Long-cycle combined contraception: less bleeding and increased subject satisfaction. *Acta Obstet Gynecol Scand.* 2006;85:517-518.
35. Barreiros FA, Guazzelli CA, de Araújo FF, Barbosa R. Bleeding patterns of women using extended regimens of the contraceptive vaginal ring. *Contraception.* 2007;75:204-208.
36. Aubeny E, Buhler M, Colau JC, Vicaut E, Zadikian M, Childs M. Oral contraception: patterns of non-compliance. The Coraliance study. *Eur J Contracept Reprod Health Care.* 2002;7:155-161.
37. Three new oral contraceptives: Seasonique, Loestrin 24 Fe, and Yaz. *Med Lett Drugs Ther.* 2006;48:77-78.
38. US Food and Drug Administration. FDA approves contraceptive for continuous use. Available at: <http://www.fda.gov/bbs/topics/NEWS/2007/NEW01637.html>. Accessed May 25, 2007.
39. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. *Contraception.* 2006;73:229-234.
40. Portman D, Anderson FD, Gibbons W. Clinical trial to evaluate the safety and efficacy of an extended-regimen oral contraceptive using continuous low-dose ethinyl estradiol. *Contraception.* 2005;72:230.
41. Lybrel [product information]. Philadelphia, Pa: Wyeth Pharmaceuticals Inc.; 2007.
42. Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. *Am J Obstet Gynecol.* 2006;195:935-941.
43. Shulman LP. The use of triphasic oral contraceptives in a continuous use regimen. *Contraception.* 2005;72:105-110.
44. Sulak PJ, Carl J, Gopalakrishnan I, Coffee A, Kuehl TJ. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. *Contraception.* 2004;70:281-287.